JP2002544167A5 - - Google Patents

Info

Publication number

JP2002544167A5

JP2002544167A5 JP2000616798A JP2000616798A JP2002544167A5 JP 2002544167 A5 JP2002544167 A5 JP 2002544167A5 JP 2000616798 A JP2000616798 A JP 2000616798A JP 2000616798 A JP2000616798 A JP 2000616798A JP 2002544167 A5 JP2002544167 A5 JP 2002544167A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

xenograft

day

recipient

rejection

Prior art date

2000-05-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 150000001875 compounds Chemical class 0.000 description 6
• 230000001506 immunosuppresive effect Effects 0.000 description 6
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 6
• 229960000951 mycophenolic acid Drugs 0.000 description 5
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 210000001124 body fluid Anatomy 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000003814 drug Substances 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 239000003463 adsorbent Substances 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• -1 MPA sodium salt Chemical class 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000000034 method Methods 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1